Investors

CEO Message

Yoshikazu Nakamura President and CEO

We have been developing our business with aptamer drug discovery by utilizing the "three-dimensional folding" capability of single-strand nucleic acids (especially RNA).

Until recently, we have focused on in-house drug discovery at the discovery stage and collaborative research with pharmaceutical companies, but in 2018, we started clinical studies in the U.S. using our own product, RBM-007, for age-related macular degeneration (wet AMD), and completed the Phase II trials last year. As a result, the efficacy of RBM-007 has been established, showing the clinical POC (Proof of Concept, meaning that the administered drug is shown to have the intended efficacy and safety in human clinical trials).

More than 100 million people worldwide suffer from wet AMD, and the number of patients is expected to increase further with the progress of aging population.

Although there are existing drugs for wet AMD, their efficacy is insufficient and the risk of blindness cannot be eliminated, so wet AMD is still a disease with unmet medical needs. We expect that our RBM-007 will contribute to the treatment of wet AMD through its new “mode of pharmacological action (MoA)" which is not found in existing drugs.

Moreover, we have completed a Phase I study of RBM-007 for achondroplasia (ACH) as our second clinical project, and a Phase II study is currently under way in pediatric ACH patients. We intend to further promote these projects and transform ourselves from a discovery-stage company to a clinical-stage company.


We would like to express our deepest gratitude to the many people who have supported us and shared our "dream" since we were listed on the Tokyo Stock Exchange Mothers in September 2014. We will continue to make further efforts to realize this dream.

Yoshikazu Nakamura, President and CEO
December 2023

Corporate Philosophy

Meeting Unmet Medical Needs (medical needs of diseases for which no effective treatments are available)
Regardless of the progress made in science and technology, many medical needs remain unmet for cancer, immune disorders, and other incurable diseases. Our objective is to discover innovative aptamer medicines for difficult to treat and incurable diseases in collaboration with other pharmaceutical companies. We plan to launch aptamer medicines as soon as possible to contribute to the health of people.

Fundamental policies for realizing the corporate philosophy

  • As a corporation involved in the research and development of pharmaceutical drugs for human life and health, we conduct research based on cutting-edge science and technology with an emphasis on high ethical standards.
  • To maximize corporate value and fulfill our social responsibility, we work to strengthen our commitment to the Structure of Corporate Governance and maintain compliance and the appropriate corporate execution of business.
  • As a listed corporation, we observe the Standards of Corporate Action developed by the Tokyo Stock Exchange, enhance the disclosure of corporate information, secure the transparency of corporate management, and ensure accountability. Furthermore, we maintain and develop good relationships with shareholders, customers, the local community and other stakeholders.